{"protocolSection": {"identificationModule": {"nctId": "NCT00751114", "orgStudyIdInfo": {"id": "LANTU_C_02761"}, "secondaryIdInfos": [{"id": "2008-000516-32", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients", "officialTitle": "Superiority Study of Insulin Glargine Over Sitagliptin in Insulin-na\u00efve Patients With Type 2 Diabetes Treated With Metformin and Not Adequately Controlled", "acronym": "EASIE"}, "statusModule": {"statusVerifiedDate": "2012-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-11"}, "primaryCompletionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-09-10", "studyFirstSubmitQcDate": "2008-09-10", "studyFirstPostDateStruct": {"date": "2008-09-11", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-07-06", "resultsFirstSubmitQcDate": "2012-08-14", "resultsFirstPostDateStruct": {"date": "2012-08-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-09-03", "lastUpdatePostDateStruct": {"date": "2012-09-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary objective was to demonstrate the superiority of insulin glargine over sitagliptin in reducing Glycosylated Hemoglobin A1c (HbA1c) from baseline to the end of the treatment period.\n\nSecondary objective was to assess the effect of insulin glargine in comparison with sitagliptin on:\n\n* HbA1c level\n* Fasting Plasma Glucose (FPG)\n* 7-point plasma glucose (PG) profiles\n* Percentage of patients with HbA1c \\<7% and \\<6.5%\n\nSafety objectives consisted of:\n\n* Hypoglycemia occurrence\n* Body weight\n* Overall safety"}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 515, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Insulin Glargine", "type": "EXPERIMENTAL", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L).", "interventionNames": ["Drug: Insulin Glargine", "Drug: Metformin"]}, {"label": "Sitagliptin", "type": "ACTIVE_COMPARATOR", "description": "Dose of 100 mg once a day administered with or without food.", "interventionNames": ["Drug: Sitagliptin", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Insulin Glargine", "description": "Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar\u00ae pen (3 mL).", "armGroupLabels": ["Insulin Glargine"], "otherNames": ["Lantus\u00ae"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "Oral administration. 100 mg film-coated tablets.", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia\u00ae"]}, {"type": "DRUG", "name": "Metformin", "description": "Patients continued with metformin as usual oral anti-diabetic treatment.", "armGroupLabels": ["Insulin Glargine", "Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "HbA1c: Change From Baseline to Study Endpoint", "description": "Change in HbA1c from baseline to study endpoint defined as the last available HbA1c value measured during the 24-week treatment period.", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14"}], "secondaryOutcomes": [{"measure": "HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 7% at Study Endpoint", "timeFrame": "study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14"}, {"measure": "HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 6.5% at Study Endpoint", "timeFrame": "study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14"}, {"measure": "Self-monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint", "description": "SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed).\n\nStudy endpoint was defined as the last available SMFPG mean value collected on-treatment.\n\nChange= study endpoint - baseline", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value"}, {"measure": "7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint", "description": "7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime.\n\nChange = study endpoint - baseline.", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14"}, {"measure": "Insulin Dose in the Insulin Glargine Group", "description": "Daily dose at the face-to-face visits.", "timeFrame": "visit 4 (week 2), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16), visit 14 (week 24), first dose received defined as first available value, study endpoint defined as last available value"}, {"measure": "Lipid Profile: Change From Baseline to Study Endpoint", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14"}, {"measure": "Change in Body Weight From Baseline to Study Endpoint", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value"}, {"measure": "Number of Patients With at Least One Episode of Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement \\<= 70mg/dL \\[3.9 mmol/L\\]", "timeFrame": "During the treatment phase (24 weeks) plus 7 days after last dose"}, {"measure": "Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia", "description": "Severe symptomatic hypoglycemia was defined as an event with clinical symptoms which required assistance of another person and with either a Plasma Glucose level \\< 36 mg/dL (2 mmol/L) or with a prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration", "timeFrame": "During the treatment phase (24 weeks) plus 7 days after last dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* With type 2 diabetes diagnosed for at least 6 months,\n* Not previously treated with insulin,\n* On metformin for at least 3 months and a stable minimal dose of 1 g/day for at least 2 months\n* HbA1c \u2265 7 and \\< 11 %,\n* Body Mass Index (BMI) between 25 and 45 kg/m\u00b2 inclusively,\n* Ability and willingness to perform plasma glucose (PG) monitoring using the Sponsor-provided PG meter and to complete the patient diary,\n* Signed informed consent obtained prior any study procedures,\n* Willingness and ability to comply with the study protocol.\n\nExclusion Criteria:\n\n* Treatment with oral antidiabetic drugs other than metformin within the last 3 months,\n* Previous treatment with the combination of metformin + sulfonylurea for more than 1 year,\n* Previous treatment with Glucagon Like Peptide-1 (GLP-1) agonists or DiPeptidyl Peptidase (DPP) IV inhibitors,\n* FPG (assessed by central laboratory measurement) \u2265 280 mg/dL (15.4 mmol/L),\n* Diabetes other than type 2 diabetes (e.g. secondary to pancreatic disorders, drug or chemical agents intake...),\n* Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method),\n* In-patient care,\n* Active proliferative retinopathy, as defined by a photocoagulation or vitrectomy occurrence in the 6 months prior to visit 1, or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgical treatment during the study (an optic fundus examination should have been performed within the 2 years prior to study entry),\n* Impaired renal function: serum creatinine \u2265 1.5 mg/dL (\u2265 133\u00b5mol/L) or \u2265 1.4 mg/dL (\u2265 124 \u00b5mol/L) in men and women, respectively,\n* History of sensitivity to the study drugs or to drugs with a similar chemical structure,\n* Impaired hepatic function: alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\> 3 x upper limit of normal range,\n* Treatment with systemic corticosteroids within the 3 months prior to study entry or likelihood of requiring treatment during the study that are not permitted during the study (exception: in case of chronic adrenal insufficiency, systemic glucosteroids are accepted only if the disease is stable and the treatment dose stable for at least 3 months before study entry),\n* Alcohol or drug abuse within the last year,\n* Night shift worker,\n* Presence of any condition (medical, psychological, social or geographical), current or anticipated that the investigator feels would compromise the patient's safety or limit the patient successful participation in the study,\n* Treatment with weight loss medications (e.g. sibutramine, orlistat, rimonabant) within the last 3 months,\n* Participation in another clinical trial within the month prior to visit 1,\n* History of pancreatitis.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "35 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Sciences & Operations", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sanofi-Aventis Administrative Office", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Vienna", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Sao Paulo", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Bogota", "country": "Colombia", "geoPoint": {"lat": 4.60971, "lon": -74.08175}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Cairo", "country": "Egypt", "geoPoint": {"lat": 30.06263, "lon": 31.24967}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Kallithea", "country": "Greece", "geoPoint": {"lat": 37.95, "lon": 23.7}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Hong Kong", "country": "Hong Kong", "geoPoint": {"lat": 22.27832, "lon": 114.17469}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Mumbai", "country": "India", "geoPoint": {"lat": 19.07283, "lon": 72.88261}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Natanya", "country": "Israel"}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Beirut", "country": "Lebanon", "geoPoint": {"lat": 33.88894, "lon": 35.49442}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Col. Coyoacan", "country": "Mexico"}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Gouda", "country": "Netherlands", "geoPoint": {"lat": 52.01667, "lon": 4.70833}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Porto Salvo", "country": "Portugal", "geoPoint": {"lat": 38.71745, "lon": -9.29833}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"facility": "Sanofi-Aventis Administrative Office", "city": "Guildford Surrey", "country": "United Kingdom", "geoPoint": {"lat": 51.23536, "lon": -0.57427}}]}, "referencesModule": {"references": [{"pmid": "22683131", "type": "RESULT", "citation": "Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V; EASIE investigators. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012 Jun 16;379(9833):2262-9. doi: 10.1016/S0140-6736(12)60439-5. Epub 2012 Jun 9."}, {"pmid": "25283485", "type": "DERIVED", "citation": "Chan JC, Aschner P, Owens DR, Picard S, Vincent M, Dain MP, Pilorget V, Loizeau V, Echtay A, Fonseca V. Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial. J Diabetes Complications. 2015 Jan-Feb;29(1):134-41. doi: 10.1016/j.jdiacomp.2014.08.007. Epub 2014 Aug 27."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 732 patients were screened in 96 centers in 17 countries. The study included an initial 2-week screening period. A total of 217 patients were screen failures. The main reason for screen failure was Glycosylated Hemoglobin A1c (HbA1c) inclusion criterion not met (146 patients).", "recruitmentDetails": "EASIE was a multicenter, international, randomized, open-label trial conducted from November 12, 2008 to July 28, 2011.", "groups": [{"id": "FG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the Fasting Plasma Glucose (FPG) target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "FG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "randomized", "numSubjects": "250"}, {"groupId": "FG001", "numSubjects": "265"}]}, {"type": "TREATED = Safety Population", "achievements": [{"groupId": "FG000", "comment": "safety population: randomized patients who received at least one dose of investigational product", "numSubjects": "237"}, {"groupId": "FG001", "numSubjects": "264"}]}, {"type": "mITT Population", "achievements": [{"groupId": "FG000", "comment": "modified Intent-To-Treat population: treated patients with at least 1 on-treatment efficacy measure", "numSubjects": "227"}, {"groupId": "FG001", "numSubjects": "253"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "212"}, {"groupId": "FG001", "numSubjects": "233"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "32"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "Not Treated", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Out of country for 2 months", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Move to another city", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "BG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "227"}, {"groupId": "BG001", "value": "253"}, {"groupId": "BG002", "value": "480"}]}], "measures": [{"title": "Age Continuous", "description": "mITT population", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.9", "spread": "8.9"}, {"groupId": "BG001", "value": "53.3", "spread": "8.7"}, {"groupId": "BG002", "value": "53.6", "spread": "8.8"}]}]}]}, {"title": "Sex/Gender, Customized", "description": "mITT population", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "114"}, {"groupId": "BG001", "value": "132"}, {"groupId": "BG002", "value": "246"}]}]}, {"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "113"}, {"groupId": "BG001", "value": "121"}, {"groupId": "BG002", "value": "234"}]}]}]}, {"title": "Body Weight", "description": "mITT population", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "83.4", "spread": "18.2"}, {"groupId": "BG001", "value": "84.2", "spread": "18.3"}, {"groupId": "BG002", "value": "83.8", "spread": "18.2"}]}]}]}, {"title": "Body Mass Index", "description": "mITT population", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m\u00b2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "31.05", "spread": "4.93"}, {"groupId": "BG001", "value": "31.13", "spread": "4.95"}, {"groupId": "BG002", "value": "31.09", "spread": "4.93"}]}]}]}, {"title": "Systolic Blood Pressure", "description": "mITT population", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "129.8", "spread": "13.3"}, {"groupId": "BG001", "value": "131.7", "spread": "15.1"}, {"groupId": "BG002", "value": "130.8", "spread": "14.3"}]}]}]}, {"title": "Diastolic Blood Pressure", "description": "mITT population", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79.5", "spread": "8.7"}, {"groupId": "BG001", "value": "80.0", "spread": "8.3"}, {"groupId": "BG002", "value": "79.7", "spread": "8.5"}]}]}]}, {"title": "Heart Rate", "description": "mITT population", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "beats/min", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "75.6", "spread": "8.7"}, {"groupId": "BG001", "value": "76.3", "spread": "9.3"}, {"groupId": "BG002", "value": "76.0", "spread": "9.0"}]}]}]}, {"title": "Duration of diabetes", "description": "mITT population", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.9", "lowerLimit": "1.9", "upperLimit": "8.2"}, {"groupId": "BG001", "value": "4.8", "lowerLimit": "1.9", "upperLimit": "8.2"}, {"groupId": "BG002", "value": "4.5", "lowerLimit": "1.9", "upperLimit": "8.2"}]}]}]}, {"title": "At least one diabetic late complication", "description": "mITT population\n\nDiabetic late complications: myocardial infarction, angina pectoris, coronary artery disease, heart failure, stroke, transient ischemic attack, peripheral vascular disease, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Yes", "categories": [{"measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "67"}, {"groupId": "BG002", "value": "132"}]}]}, {"title": "No", "categories": [{"measurements": [{"groupId": "BG000", "value": "162"}, {"groupId": "BG001", "value": "186"}, {"groupId": "BG002", "value": "348"}]}]}]}, {"title": "Glycosylated Hemoglobin A1c (HbA1c)", "description": "mITT population", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.5", "spread": "1.0"}, {"groupId": "BG001", "value": "8.5", "spread": "1.1"}, {"groupId": "BG002", "value": "8.5", "spread": "1.1"}]}]}]}, {"title": "Fasting Plasma Glucose", "description": "mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "163.6", "spread": "42.0"}, {"groupId": "BG001", "value": "171.1", "spread": "41.5"}, {"groupId": "BG002", "value": "167.5", "spread": "41.9"}]}]}]}, {"title": "Self-monitored Fasting Plasma Glucose", "description": "mITT population but due to missing values, N=216 for Insulin Glargine and N=244 for Sitagliptin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "163.9", "spread": "37.6"}, {"groupId": "BG001", "value": "166.7", "spread": "38.2"}, {"groupId": "BG002", "value": "165.4", "spread": "37.9"}]}]}]}, {"title": "Total Cholesterol", "description": "mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "185.9", "spread": "41.4"}, {"groupId": "BG001", "value": "187.1", "spread": "39.0"}, {"groupId": "BG002", "value": "186.5", "spread": "40.1"}]}]}]}, {"title": "High-Density Lipoprotein (HDL) Cholesterol", "description": "mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "46.2", "spread": "14.6"}, {"groupId": "BG001", "value": "45.0", "spread": "11.2"}, {"groupId": "BG002", "value": "45.6", "spread": "12.9"}]}]}]}, {"title": "Low-Density Lipoprotein (LDL) Cholesterol", "description": "mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "112.7", "spread": "36.2"}, {"groupId": "BG001", "value": "114.2", "spread": "33.2"}, {"groupId": "BG002", "value": "113.5", "spread": "34.6"}]}]}]}, {"title": "Triglycerides", "description": "mITT population but due to missing values, N=225 for Insulin Glargine and N=248 for Sitagliptin", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "190.9", "spread": "142.0"}, {"groupId": "BG001", "value": "185.7", "spread": "114.6"}, {"groupId": "BG002", "value": "188.2", "spread": "128.3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "HbA1c: Change From Baseline to Study Endpoint", "description": "Change in HbA1c from baseline to study endpoint defined as the last available HbA1c value measured during the 24-week treatment period.", "populationDescription": "The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.\n\nThe Last Observation Carried Forward method was used for imputing missing data for the end of treatment value.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "248"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.72", "spread": "0.06"}, {"groupId": "OG001", "value": "-1.13", "spread": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "H0: no difference between insulin glargine mean HbA1c change and sitagliptin mean HbA1c change\n\nH1: difference between insulin glargine mean HbA1c change and sitagliptin mean HbA1c change\n\nAssuming:\n\n* Estimated standard deviation of the change in HbA1c of 1.3%\n* Expected mean difference to be detected of 0.4%\n* Alpha risk of 5% (two-sided)\n* Power of 90%\n* Equal sample size in each treatment group (1:1 randomization)\n\nA total number of 446 evaluable patients (223 in each group) was required", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "An analysis of covariance (ANCOVA) was performed, with the HbA1c change from baseline to last on-treatment measurement as dependent variable, treatment as fixed effect and the corresponding baseline HbA1c value as covariate", "statisticalMethod": "ANCOVA", "paramType": "adjusted mean difference", "paramValue": "-0.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.77", "ciUpperLimit": "-0.42", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.09", "estimateComment": "Difference (Insulin glargine - Sitagliptin)"}]}, {"type": "SECONDARY", "title": "HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 7% at Study Endpoint", "populationDescription": "The population analyzed for this outcome measure consisted of the subset of mITT patients who had endpoint measurements.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "248"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67.9"}, {"groupId": "OG001", "value": "41.9"}]}]}]}, {"type": "SECONDARY", "title": "HbA1c Response Rate: Percentage of Patients Who Reach the Target of HbA1c < 6.5% at Study Endpoint", "populationDescription": "The population analyzed for this outcome measure consisted of the subset of mITT patients who had endpoint measurements.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "224"}, {"groupId": "OG001", "value": "248"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "40.2"}, {"groupId": "OG001", "value": "16.9"}]}]}]}, {"type": "SECONDARY", "title": "Self-monitored Fasting Plasma Glucose (SMFPG) Mean : Change From Baseline to Study Endpoint", "description": "SMFPG mean = mean of the fasting plasma glucose values recorded on the 6 consecutive days before the visit (at least 3 values needed).\n\nStudy endpoint was defined as the last available SMFPG mean value collected on-treatment.\n\nChange= study endpoint - baseline", "populationDescription": "The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.\n\nAdjusted means were estimated from ANCOVA model using baseline value as covariate.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "214"}, {"groupId": "OG001", "value": "244"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-60.52", "spread": "1.85"}, {"groupId": "OG001", "value": "-19.35", "spread": "1.73"}]}]}]}, {"type": "SECONDARY", "title": "7-point Plasma Glucose Profile: Change From Baseline to Study Endpoint", "description": "7-point plasma glucose recorded before and after breakfast, before and after lunch, before and after dinner and at bedtime.\n\nChange = study endpoint - baseline.", "populationDescription": "The population analyzed for this outcome measure consisted of the subset of mITT patients who had valid 7-point plasma glucose profiles (4 points needed for a valid profile) both at baseline and endpoint.\n\nDepending on the time point, few values were missing.\n\nAdjusted means were estimated from ANCOVA model using baseline value as covariate.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "203"}, {"groupId": "OG001", "value": "227"}]}], "classes": [{"title": "Before breakfast (N ig = 203 & N s = 226)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-59.90", "spread": "2.02"}, {"groupId": "OG001", "value": "-20.39", "spread": "1.91"}]}]}, {"title": "After breakfast (N ig = 202 & N s = 220)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-66.25", "spread": "3.03"}, {"groupId": "OG001", "value": "-36.41", "spread": "2.90"}]}]}, {"title": "Before lunch (N ig = 201 & N s = 223)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-48.00", "spread": "2.33"}, {"groupId": "OG001", "value": "-19.82", "spread": "2.21"}]}]}, {"title": "After lunch (N ig = 202 & N s = 226)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-45.54", "spread": "2.82"}, {"groupId": "OG001", "value": "-26.10", "spread": "2.66"}]}]}, {"title": "Before dinner (N ig = 199 & N s = 223)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-40.68", "spread": "2.61"}, {"groupId": "OG001", "value": "-25.07", "spread": "2.47"}]}]}, {"title": "After dinner (N ig = 196 & N s = 220)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-45.88", "spread": "2.69"}, {"groupId": "OG001", "value": "-33.78", "spread": "2.54"}]}]}, {"title": "At bedtime (N ig = 177 & N s = 210)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-45.58", "spread": "3.15"}, {"groupId": "OG001", "value": "-31.16", "spread": "2.89"}]}]}]}, {"type": "SECONDARY", "title": "Insulin Dose in the Insulin Glargine Group", "description": "Daily dose at the face-to-face visits.", "populationDescription": "The population analyzed for this outcome was the safety population defined as randomized patients who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "unit per kg body weight", "timeFrame": "visit 4 (week 2), visit 8 (week 6), visit 11 (week 12), visit 12 (week 16), visit 14 (week 24), first dose received defined as first available value, study endpoint defined as last available value", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}]}], "classes": [{"title": "First dose received N=236", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.19", "spread": "0.03"}]}]}, {"title": "Visit 4 (week 2) N=230", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "spread": "0.08"}]}]}, {"title": "Visit 8 (week 6) N=222", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.38", "spread": "0.16"}]}]}, {"title": "Visit 11 (week 12) N=219", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.45", "spread": "0.20"}]}]}, {"title": "Visit 12 (week 16) N=214", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.48", "spread": "0.23"}]}]}, {"title": "Visit 14 (week 24) N=220", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.50", "spread": "0.26"}]}]}, {"title": "Study endpoint N=237", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.49", "spread": "0.26"}]}]}]}, {"type": "SECONDARY", "title": "Lipid Profile: Change From Baseline to Study Endpoint", "populationDescription": "The population analyzed for this outcome measure consisted of the subset of mITT patients who had both baseline and endpoint measurements.\n\nAdjusted means were estimated from ANCOVA model using baseline value as covariate.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 11 (week 12) if value not available at visit 14", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "222"}, {"groupId": "OG001", "value": "243"}]}], "classes": [{"title": "Change in Total Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "-7.94", "spread": "2.06"}, {"groupId": "OG001", "value": "-1.54", "spread": "1.97"}]}]}, {"title": "Change in LDL Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.68", "spread": "1.71"}, {"groupId": "OG001", "value": "-0.19", "spread": "1.63"}]}]}, {"title": "Change in HDL Cholesterol", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.13", "spread": "0.54"}, {"groupId": "OG001", "value": "0.57", "spread": "0.52"}]}]}, {"title": "Change in Triglycerides", "categories": [{"measurements": [{"groupId": "OG000", "value": "-34.07", "spread": "8.14"}, {"groupId": "OG001", "value": "0.31", "spread": "7.78"}]}]}]}, {"type": "SECONDARY", "title": "Change in Body Weight From Baseline to Study Endpoint", "populationDescription": "The population analyzed for this outcome measure consisted of the subset of the safety population (treated patients) who had both baseline and endpoint measurements.\n\nAdjusted means were estimated from ANCOVA model using baseline value as covariate.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "baseline (week 0), study endpoint: visit 14 (week 24) or visit 12 (week 16) or visit 11 (week 12) or visit 8 (week 6) depending on last available value", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "227"}, {"groupId": "OG001", "value": "255"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.44", "spread": "0.22"}, {"groupId": "OG001", "value": "-1.08", "spread": "0.20"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With at Least One Episode of Symptomatic Hypoglycemia", "description": "Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemia confirmed or not by a plasma glucose measurement \\<= 70mg/dL \\[3.9 mmol/L\\]", "populationDescription": "The population analyzed for this outcome measure was the safety population (treated patients)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "During the treatment phase (24 weeks) plus 7 days after last dose", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "264"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "108"}, {"groupId": "OG001", "value": "35"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients With at Least One Episode of Severe Symptomatic Hypoglycemia", "description": "Severe symptomatic hypoglycemia was defined as an event with clinical symptoms which required assistance of another person and with either a Plasma Glucose level \\< 36 mg/dL (2 mmol/L) or with a prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration", "populationDescription": "The population analyzed for this outcome measure was the safety population (treated patients)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "During the treatment phase (24 weeks) plus 7 days after last dose", "groups": [{"id": "OG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)"}, {"id": "OG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "237"}, {"groupId": "OG001", "value": "264"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Adverse events were assessed throughout the study (24 weeks). Mean duration of exposure to insulin glargine was 157.7 \u00b1 40.9 days (ranging from 1 to 211 days) and 160.8 \u00b1 33.7 days to sitagliptin (ranging from 14 to 262 days).", "eventGroups": [{"id": "EG000", "title": "Insulin Glargine", "description": "Administered once a day in the evening at dinner or at bedtime with a starting dose 0.2 U/kg. Then, the doses were to be individually adjusted, following a titration algorithm, to reach the FPG target: 70mg/dL\\<FPG\u2264100mg/dL (3.9mmol/L\\<FPG\u22645.5mmol/L)", "seriousNumAffected": 15, "seriousNumAtRisk": 237, "otherNumAffected": 27, "otherNumAtRisk": 237}, {"id": "EG001", "title": "Sitagliptin", "description": "Dose of 100 mg once a day administered with or without food", "seriousNumAffected": 8, "seriousNumAtRisk": 264, "otherNumAffected": 41, "otherNumAtRisk": 264}], "seriousEvents": [{"term": "Haemorrhagic anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Diverticulum intestinal", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Impaired gastric emptying", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Vascular pseudoaneurysm", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Hypoglycaemic unconsciousness", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Kaposi's sarcoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Carotid artery occlusion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Loss of consciousness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Nerve compression", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Calculus ureteric", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 264}]}, {"term": "Orthostatic hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}, {"term": "Peripheral arterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 264}]}], "otherEvents": [{"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 264}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 264}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDra", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 237}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 264}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 45 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Trial Transparency Team", "organization": "sanofi-aventis", "email": "Contact-US@sanofi.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Romania"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}, {"id": "M10365", "name": "Insulin", "relevance": "LOW"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}